Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Among authors: wszolek m. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Culp SH, et al. Among authors: wszolek mf. J Urol. 2014 Jan;191(1):40-7. doi: 10.1016/j.juro.2013.07.061. Epub 2013 Jul 30. J Urol. 2014. PMID: 23911605 Free PMC article.
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Giacalone NJ, et al. Among authors: wszolek mf. Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9. Eur Urol. 2017. PMID: 28081860
Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA. Sanchez A, et al. Among authors: wszolek mf. J Urol. 2018 Feb;199(2):407-415. doi: 10.1016/j.juro.2017.08.106. Epub 2017 Sep 1. J Urol. 2018. PMID: 28870862
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. Liu Q, et al. Among authors: wszolek mf. Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7. Oncogene. 2018. PMID: 29511347 Free PMC article.
Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
Pieretti A, Krasnow R, Drumm M, Gusev A, Dahl DM, McGovern F, Blute ML, Shipley WU, Efstathiou JA, Feldman AS, Wszolek MF. Pieretti A, et al. Among authors: wszolek mf. J Urol. 2021 Jul;206(1):29-36. doi: 10.1097/JU.0000000000001696. Epub 2021 Feb 22. J Urol. 2021. PMID: 33617327
43 results